Tumor markers in clinical use

SMK Gamage; Chamath  Ranaweera; Tracie Cheng; Sharmin Aktar; Vinod Gopalan; Farhadul Islam

doi:10.2174/9789815079364123010005

Tumor markers in clinical use

SMK Gamage^*, Chamath Ranaweera, Tracie Cheng, Sharmin Aktar, Vinod Gopalan, Farhadul Islam

^*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Research › peer-review

Abstract

Despite ever-growing experimental evidence for the utility of a wide range of tumour markers, only a handful are understood to be useful in clinical applications. Tumour markers are useful for screening and diagnosis of cancers, prognostication, guiding treatment pathways and post-treatment surveillance studies. The tumour makers play a significant role in cancer care and the markers included in the current treatment guidelines will be discussed in detail in this chapter. The utility of the tumour markers in the management of colorectal, breast, thyroid, hepatobiliary, pancreatic, ovarian, testicular, neuroendocrine and prostate cancer are detailed herein to provide an update on the current use of tumour markers in the clinical settings.

Original language	English
Title of host publication	Current Cancer Biomarkers
Publisher	Bentham Science Publishers
Pages	11-32
Number of pages	22
Volume	1
Edition	1
DOIs	https://doi.org/10.2174/9789815079364123010005
Publication status	Published - Jan 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/9789815079364123010005

Cite this

@inbook{937bdd4599724f91923e70cc86c2b2b3,

title = "Tumor markers in clinical use",

abstract = "Despite ever-growing experimental evidence for the utility of a wide range of tumour markers, only a handful are understood to be useful in clinical applications. Tumour markers are useful for screening and diagnosis of cancers, prognostication, guiding treatment pathways and post-treatment surveillance studies. The tumour makers play a significant role in cancer care and the markers included in the current treatment guidelines will be discussed in detail in this chapter. The utility of the tumour markers in the management of colorectal, breast, thyroid, hepatobiliary, pancreatic, ovarian, testicular, neuroendocrine and prostate cancer are detailed herein to provide an update on the current use of tumour markers in the clinical settings. ",

author = "SMK Gamage and Chamath Ranaweera and Tracie Cheng and Sharmin Aktar and Vinod Gopalan and Farhadul Islam",

year = "2023",

month = jan,

doi = "10.2174/9789815079364123010005",

language = "English",

volume = "1",

pages = "11--32",

booktitle = "Current Cancer Biomarkers",

publisher = "Bentham Science Publishers",

address = "United Arab Emirates",

edition = "1",

}

TY - CHAP

T1 - Tumor markers in clinical use

AU - Gamage, SMK

AU - Ranaweera, Chamath

AU - Cheng, Tracie

AU - Aktar, Sharmin

AU - Gopalan, Vinod

AU - Islam, Farhadul

PY - 2023/1

Y1 - 2023/1

N2 - Despite ever-growing experimental evidence for the utility of a wide range of tumour markers, only a handful are understood to be useful in clinical applications. Tumour markers are useful for screening and diagnosis of cancers, prognostication, guiding treatment pathways and post-treatment surveillance studies. The tumour makers play a significant role in cancer care and the markers included in the current treatment guidelines will be discussed in detail in this chapter. The utility of the tumour markers in the management of colorectal, breast, thyroid, hepatobiliary, pancreatic, ovarian, testicular, neuroendocrine and prostate cancer are detailed herein to provide an update on the current use of tumour markers in the clinical settings.

AB - Despite ever-growing experimental evidence for the utility of a wide range of tumour markers, only a handful are understood to be useful in clinical applications. Tumour markers are useful for screening and diagnosis of cancers, prognostication, guiding treatment pathways and post-treatment surveillance studies. The tumour makers play a significant role in cancer care and the markers included in the current treatment guidelines will be discussed in detail in this chapter. The utility of the tumour markers in the management of colorectal, breast, thyroid, hepatobiliary, pancreatic, ovarian, testicular, neuroendocrine and prostate cancer are detailed herein to provide an update on the current use of tumour markers in the clinical settings.

U2 - 10.2174/9789815079364123010005

DO - 10.2174/9789815079364123010005

M3 - Chapter

VL - 1

SP - 11

EP - 32

BT - Current Cancer Biomarkers

PB - Bentham Science Publishers

ER -

Tumor markers in clinical use

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this